Mainz Biomed (NASDAQ:MYNZ – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($3.60) per share and revenue of $0.25 million for the quarter.
Mainz Biomed Stock Down 10.5 %
Shares of NASDAQ:MYNZ opened at $2.98 on Friday. The company has a market cap of $5.96 million, a price-to-earnings ratio of -0.05 and a beta of 0.33. The business has a 50 day moving average price of $5.26 and a 200 day moving average price of $7.04. Mainz Biomed has a twelve month low of $2.65 and a twelve month high of $45.20.
Analyst Upgrades and Downgrades
Separately, Maxim Group assumed coverage on Mainz Biomed in a research report on Friday, February 14th. They issued a “buy” rating and a $14.00 price objective for the company.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Recommended Stories
- Five stocks we like better than Mainz Biomed
- What is the Dogs of the Dow Strategy? Overview and Examples
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
